Psychedelic Drugs

Researchers investigating the psychedelic drug DOPR discovered that very low doses can enhance motivation in low-performing mice—without triggering behaviors linked to hallucinations. The findings point to the therapeutic potential of psychedelics at doses too low to alter perception.

In a groundbreaking case report, scientists administered psilocybin to a woman in a minimally conscious state and observed increased brain complexity and new spontaneous behavior—offering a glimpse into how psychedelics might influence consciousness in severe brain injury patients.

Psilocybin therapy produced surprising benefits in a small study of people with Parkinson’s disease. Beyond improving mood, the psychedelic treatment was linked to better motor function and cognitive performance.

New research shows that psychedelic use is often associated with changes in romantic relationships, sexual experiences, and gender identity. The study highlights how these experiences might foster self-acceptance, authenticity, and greater connection to others.

A new meta-analysis shows that reported antidepressant effects of psychedelics vary widely depending on the study design used.

A new study explores combining psilocybin microdosing with neurofeedback. The method appears feasible, though it’s unclear whether it meaningfully improves mental performance.

A new study suggests that meaningful psychedelic experiences may broaden the range of beings people see as morally worthy.

A new study suggests that emergency visits involving hallucinogens could be a warning sign for future schizophrenia, especially among younger adults.

A new brain imaging study finds LSD alters brain connectivity in unique ways, setting it apart from MDMA and amphetamine despite some shared effects.

A new case report describes how two multiple sclerosis patients showed reduced brain lesions and symptom improvement following ibogaine treatment.

Microdosing LSD has no clear benefit for ADHD, according to a new placebo-controlled clinical trial published in JAMA Psychiatry.

A study of British adults found that those who had used psychedelics were 25% less likely to report frequent bad headaches, adding to growing research on psychedelics’ potential medical benefits.

Does psilocybin affect everyone the same way? New research suggests that race and ethnicity may play a role in the long-term benefits of this psychedelic substance.

Recent findings suggest that ayahuasca improves detailed memory recall among experienced users without altering overall familiarity.

A single dose of psilocybin significantly increased emotional empathy in depressed individuals for up to two weeks.